CRISPR Screens Identify Vital lncRNAs
CMN Briefs
Nov. 12, 2024
CMN Webinar | Wednesday November 27, 2024 | 3:00 pm–4:00 pm CET / 9:00 am–10:00 am ET
Targeting Drug Resistance in Solid Tumours Using CRISPR-Directed Gene Editing
Targeting Drug Resistance in Solid Tumours Using CRISPR-Directed Gene Editing
The Gene Editing Institute at ChristianaCare is a worldwide leader in CRISPR gene editing technology. As the only institute of its kind based within a community health care system, the Gene Editing Institute has a unique opportunity to take a patient-first approach in all its research by working side by side with oncologists and other medical experts to improve the lives of people with cancer and inherited diseases.
Since 2015, its researchers have led several ground-breaking firsts in the field that will help bring treatments to patients quickly and safely. They recently discovered that disabling a lung cancer gene called NRF2 using CRISPR gene editing allows chemotherapy work better to target cancer cells. Lung cancer resistance to chemotherapy has long been elusive. The Gene Editing Institute, working with its spin out company CorriXR Therapeutics, is close to approval from the FDA to start clinical trials in humans.
What you will learn about in this webinar:
- Development of a unique strategy to disrupt NRF2, a key gene involved in drug resistance in solid tumours, to augment standard of care therapies
- Importance of understanding the impact of on-site mutagenesis after CRISPR-directed gene editing on downstream phenotypic outcomes
- Application of current strategy to other clinically-relevant genes involved in drug resistance in solid tumours
Webinar Programme (CET time zone):
- 15.00 Welcome and introduction by Karen O'Hanlon Cohrt PhD., Editor-in-chief, CRISPR Medicine News
- 15.05 Kelly Banas PhD / Associate Director of Research, ChristianaCare Gene Editing Institute, Newark, United States
- 15.40 Q & A with Kelly Banas
- 15.55 Close by CRISPR Medicine News
Speaker | Title:
Kelly Banas PhD / Associate Director of Research, ChristianaCare Gene Editing Institute, Newark, United States | Targeting Drug Resistance in Solid Tumours Using CRISPR-Directed Gene Editing
Speakers
Kelly Banas PhD / Associate Director of Research, ChristianaCare Gene Editing Institute, Newark, United States
Kelly Banas is the Associate Director of Research at the ChristianaCare Gene Editing Institute. She leads a team of researchers working to identify new clinically-relevant genomic targets as well as working to understand the specificity and safety of CRISPR-Cas systems as a therapeutic modality.
Her previous research has led to an innovative foundational approach to the treatment of solid tumours using CRISPR-directed gene editing, which is currently being developed for Investigational New Drug status. She received her Ph.D. in 2021 from the University of Delaware, where she studied the short- and long-term effects of CRISPR as a treatment for solid tumours.
Read our previous interview with Kelly Banas here.
Sign up to the webinar
Targeting Drug Resistance in Solid Tumours Using CRISPR-Directed Gene Editing | Wednesday November 27, 2024 | 3:00 pm–4:00 pm CET / 9:00 am–10:00 am ET
CMN Articles - Cancer
